F901318 - A Phase I, Double-Blind, Placebo Controlled, Multiple Ascending Oral Dose Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 27 May 2017
At a glance
- Drugs F 901318 (Primary)
- Indications Aspergillosis
- Focus Adverse reactions
- Acronyms ORALMAD
- Sponsors F2G
- 22 May 2017 Status changed from recruiting to completed.
- 13 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
- 13 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.